{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"ss-31-diabetic-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-diabetic-neuropathy/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/ss-31-diabetic-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-diabetic-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-diabetic-neuropathy/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-diabetic-neuropathy/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-diabetic-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/ss-31-diabetic-neuropathy/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"ss-31-diabetic-neuropathy","title":"SS-31 (Elamipretide) for Diabetic Neuropathy: Mitochondrial Evidence Review","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:42:02.572Z","body_excerpt":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve damage linked to chronic high blood sugar. Mitochondrial dysfunction sits at the core. Hyperglycemia drives excess reactive oxygen species inside nerve cell mitochondria. This damages cardiolipin in the inner membrane, impairs electron transport, lowers ATP output, and triggers further oxidative stress plus inflammation. Over time, axons degenerate, Schwann cells suffer, and sensory, motor, or autonomic nerves lose function. The process is degenerative: breakdown outruns repair in mitochondria-rich nerve tissue. No approved peptide reverses this; management focuses on glucose control and symptom relief.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\n2. Therefore for you: If mitochondrial oxidative damage in nerves is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\nSS-31 binds cardiolipin on the inner mitochondrial membrane. In damaged mitochondria it scavenges ROS, stabilizes membrane structure, reduces electron leak, and supports ATP production. Preclinical diabetic models show this protects cells from high-glucose injury. For someone with diabetic neuropathy the logic chain runs: if hyperglycemia has already stressed nerve mitochondria, then reducing that specific ROS burden and restoring bioenergetics could slow further axonal loss. The peptide shows no effect on healthy mitochondria, so the action is selective to stressed tissue.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes a multi-peptide stack, siblings would target other layers such as inflammation or vascular support. Here the emphasis stays on mitochondrial cardiolipin stabilization as the primary studied pathway in diabetic complications.\n\n## What the evidence actually shows\n\nAll direct data on SS-31 in diabetic models concern nephropathy, not neuropathy. A 2016 mouse study (Hou et al.) gave SS-31 to streptozotocin-diabetic mice for eight weeks and reported reduced proteinuria, less glomerular hypertrophy, lower renal fibronectin and collagen IV, plus decreased renal cell apoptosis. The mechanism tracked to lower mitochondrial ROS and preserved thioredoxin activity (preclinical, animal). A 2022 systematic review of in vivo and in vitro diabetic nephropathy studies concluded SS-31 improved kidney function markers and histopathology in diabetic rodents (preclinical). In human type 2 diabetes leukocytes ex vivo, SS-31 lowered mitochondrial ROS production and modulated ER stress (mechanistic, human cells). No published human trial has tested SS-31 for diabetic neuropathy or even diabetic nerve endpoints. Clinical trials in primary mitochondrial myopathy (phase 3, 218 patients) failed primary endpoints on 6-minute walk test; earlier smaller trials showed modest exercise gains. SS-31 received accelerated FDA approval in 2025 for Barth syndrome (rare mitochondrial disorder). Evidence inventory: zero human neuropathy trials, multiple rodent kidney studies, limited human cell mechanistic data, scattered anecdotes.\n\n## What scientists say\n\nReviews note SS-31's promise in models of diabetic kidney disease via mitochondrial protection and call for further studies to confirm translation. Neuroprotective signals appear in separate neurodegeneration models (Alzheimer's, spinal cord injury) through the same cardiolipin-ROS pathway, but diabetic neuropathy remains untested. Researchers emphasize that benefits appear selective to stressed mitochondria and that long-term human safety and efficacy data are still limited outside approved rare-disease use.\n\n## What people say on Reddit\n\nDiscussions of SS-31 center on mitochondrial support for energy, CFS, or kidney issues. A few users with small-fiber neuropathy or fluoroquino","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c3","text":"No published human clinical trials test SS-31 for diabetic neuropathy.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies absence of direct evidence for the target condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c5","text":"Phase 3 trial of SS-31 in primary mitochondrial myopathy failed primary endpoints.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s5"],"source_status":"sourced","why_material":"Documents largest human efficacy data point.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c2","text":"In diabetic mouse models SS-31 reduced proteinuria and glomerular damage via lower renal mitochondrial ROS.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Demonstrates tissue-level protection in diabetes complication model.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c1","text":"SS-31 binds cardiolipin and reduces mitochondrial ROS in stressed cells.","tier":"mechanistic","weight":0.3,"section":"Why SS-31 (Elamipretide) might help you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Core mechanism relevant to diabetic mitochondrial stress.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"Ex vivo treatment of leukocytes from type 2 diabetes patients with SS-31 lowered mitochondrial ROS.","tier":"mechanistic","weight":0.3,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Human-cell data supporting antioxidant action in diabetes.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"review","url":"https://www.mdpi.com/1422-0067/26/3/944","title":"Elamipretide: A Review of Its Structure, Mechanism of Action, and Clinical Applications","quote":"Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin.","summary":"Details cardiolipin binding and ROS reduction mechanism.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"5834869991c1be9bd2abb8d04679af944106802b93dc875053ebbceeb23432a1"},{"id":"s2","type":"pubmed","url":"https://journals.physiology.org/doi/full/10.1152/ajprenal.00574.2014","title":"Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy","quote":"This study demonstrates a protective effect of SS-31 against HG-induced renal injury via an antioxidant mechanism in diabetic nephropathy.","summary":"Mouse diabetic nephropathy study with functional and histological improvements.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"d975e06a21db61cf1b2ee49672ef849a9b82a56c208b352a1d4807f919efae92"},{"id":"s3","type":"review","url":"https://jppres.com/jppres/ss-31-for-diabetic-nephropathy/","title":"SS-31 for diabetic nephropathy","quote":"Further studies are required to confirm its findings.","summary":"Systematic review notes lack of human confirmation even for kidney.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"a5d06b40b312b7d7a7b88a7e493e0472b3176c16720482359d131d111c6a59e2"},{"id":"s4","type":"pubmed","url":"https://www.nature.com/articles/s41598-018-34251-8","title":"The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes","quote":"Our results reveal that SS-31 exerts beneficial effects on the leukocytes of T2D patients by reducing oxidative stress...","summary":"Human cell data on ROS reduction.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"035bf4d85e05e2e97d76fa48d9385ffac21e9f0255105ec23a6c30a5da8196c5"},{"id":"s5","type":"clinical_trial","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000207402","title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy","quote":"This study provides Class I evidence that elamipretide does not improve the 6MWT or fatigue at 24 weeks compared with placebo...","summary":"Phase 3 trial results.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"4c920711a3c36152692c0b5d978356fa1e24c45b013e1ab597d403e525e8f254"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"review","url":"https://www.mdpi.com/1422-0067/26/3/944","title":"Elamipretide: A Review of Its Structure, Mechanism of Action, and Clinical Applications","quote":"Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin.","summary":"Details cardiolipin binding and ROS reduction mechanism.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"5834869991c1be9bd2abb8d04679af944106802b93dc875053ebbceeb23432a1"},{"id":"s2","type":"pubmed","url":"https://journals.physiology.org/doi/full/10.1152/ajprenal.00574.2014","title":"Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy","quote":"This study demonstrates a protective effect of SS-31 against HG-induced renal injury via an antioxidant mechanism in diabetic nephropathy.","summary":"Mouse diabetic nephropathy study with functional and histological improvements.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"d975e06a21db61cf1b2ee49672ef849a9b82a56c208b352a1d4807f919efae92"},{"id":"s3","type":"review","url":"https://jppres.com/jppres/ss-31-for-diabetic-nephropathy/","title":"SS-31 for diabetic nephropathy","quote":"Further studies are required to confirm its findings.","summary":"Systematic review notes lack of human confirmation even for kidney.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"a5d06b40b312b7d7a7b88a7e493e0472b3176c16720482359d131d111c6a59e2"},{"id":"s4","type":"pubmed","url":"https://www.nature.com/articles/s41598-018-34251-8","title":"The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes","quote":"Our results reveal that SS-31 exerts beneficial effects on the leukocytes of T2D patients by reducing oxidative stress...","summary":"Human cell data on ROS reduction.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"035bf4d85e05e2e97d76fa48d9385ffac21e9f0255105ec23a6c30a5da8196c5"},{"id":"s5","type":"clinical_trial","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000207402","title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy","quote":"This study provides Class I evidence that elamipretide does not improve the 6MWT or fatigue at 24 weeks compared with placebo...","summary":"Phase 3 trial results.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"4c920711a3c36152692c0b5d978356fa1e24c45b013e1ab597d403e525e8f254"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"ss-31-diabetic-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":5,"anecdotal":0,"scientific":5,"user_reports":0,"questions":0,"evidence_ingests":0}}